Financial Performance - The corrected total operating revenue is 20,603.30 million CNY, a decrease of 9.03% compared to the same period last year[3] - The corrected operating profit is -736.09 million CNY, reflecting a decrease of 115.02% year-over-year[3] - The corrected net profit attributable to the parent company is -1,266.22 million CNY, a decrease of 123.35% compared to the previous year[3] - The corrected basic earnings per share is -0.09 CNY, representing a decrease of 122.78% year-over-year[4] - The corrected net profit attributable to the parent company after deducting non-recurring gains and losses is -2,837.11 million CNY, a decrease of 210.11% year-over-year[3] - The corrected weighted average return on net assets is -0.91%, a decrease of 122.31% compared to the previous year[4] Assets and Equity - The corrected total assets amount to 154,029.42 million CNY, an increase of 0.92% from the beginning of the reporting period[4] - The corrected net assets attributable to the parent company are 140,287.44 million CNY, reflecting a 1.50% increase from the previous year[4] Adjustments and Cautions - The adjustments were primarily due to changes in the share-based payment amount after determining the number of restricted stock participants[8] - The company emphasizes that the financial data has not yet been audited and investors should be cautious of investment risks[10]
奥精医疗(688613) - 2024 Q4 - 年度业绩预告